K
Korro Bio
Biotech & Life Sciences · Cambridge, United States · Founded 2018 · IPO 2023
Efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms MoreLess
Korro Bio is a cutting-edge biotechnology startup focused on developing innovative RNA-based therapies to treat debilitating and life-threatening diseases. The company operates in the biopharmaceutical market, targeting patients who suffer from conditions that currently have limited or no treatment options. Korro Bio's unique approach leverages RNA editing, a method that allows for precise modifications at the RNA level to alter protein function. This technique is considered superior to traditional gene editing and gene therapy because it can make single base edits, which are more accurate and potentially less risky.
The business model of Korro Bio revolves around the discovery, development, and commercialization of these RNA therapies. The company invests heavily in research and development (R&D) to create new treatments based on scientific insights and human genetics. Once a therapy is developed, Korro Bio aims to bring it to market either independently or through partnerships with larger pharmaceutical companies. Revenue is generated through the sale of these therapies, licensing agreements, and potentially through collaborations with other biotech firms.
Korro Bio serves a diverse range of clients, including healthcare providers, hospitals, and patients who are in dire need of new treatment options. The company also collaborates with academic institutions and research organizations to advance its scientific discoveries.
In summary, Korro Bio is at the forefront of RNA editing technology, striving to transform the future of medicine by providing new hope for patients worldwide. The company is driven by a mission to make groundbreaking scientific advancements accessible and effective for those suffering from severe diseases.
Keywords: RNA editing, biotechnology, biopharmaceutical, gene therapy, protein function, healthcare, R&D, innovative treatments, scientific insights, debilitating diseases.
Company overview
Korro Bio company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2018
- Headquarters
- Cambridge, United States
- Employees
- 75
- Open positions
- 7
- Dealroom signal
- 64.1
- Investment activity
- 1 companies · latest Jul 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Korro Bio funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Mar 2026 | $85M | — | Nantahala Capital Management · Kalehua Capital Management · NEA · Venrock | ↗ |
| PRIVATE PLACEMENT VCOther financing | Apr 2024 | $70M | — | Atlas Venture · Deep Track Capital · Blue Owl Capital · NEA | ↗ |
| MERGEROther financing | Nov 2023 | $0 | — | Frequency Therapeutics | — |
| PRIVATE PLACEMENT VCOther financing | Nov 2023 | $117M | — | Atlas Venture · Invus · MP Healthcare Venture Management · Point72 Ventures | ↗ |
| IPOOther financing | Jul 2023 | $0 | — | Undisclosed | ↗ |
| SERIES BOther financing | Jan 2022 | Fidelity Investments · MP Healthcare Venture Management · Wu Capital · Cormorant Asset Management | ↗ | ||
| SERIES AOther financing | Sep 2020 | Cormorant Asset Management · Qiming Venture Partners USA · Atlas Venture · NEA | — | ||
| SPINOUTOther financing | Dec 2018 | The University of Chicago · Marine Biological Laboratory | — | ||
| SEEDOther financing | Jan 2018 | Atlas Venture · NEA | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $6.4M | 0% | −$49M | -759.5% |
| 2025 | $6.4M | +181.5% | −$49M | -759.5% |
| 2024 | $2.3M | — | −$88M | -3890.1% |
| 2023 | $0 | — | −$81M | — |
| 2022 | $0 | — | −$55M | — |
| 2021 | $0 | — | −$34M | — |
Growth signals
Korro Bio website traffic
Latest recorded traffic for Korro Bio is 4.9K monthly website visits, down 10.9% over the last three months. Korro Bio's team declined 21.1% over the past year.
Hiring
Open positions at Korro Bio
Current openings linked to this company in Dealroom.
Comparisons
Korro Bio compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Korro Bio investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Korro Bio's talent
Source: Dealroom Talent Intelligence.
Investors
33 investors on Korro Bio's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Korro Bio has talent and traffic
team presence
In the news
Latest news about Korro Bio
Recent press, funding announcements, and product moves mentioning Korro Bio — open to read from the original sources.
Market sentiment
What the market is saying about Korro Bio
An AI-synthesized read of the highest-engagement posts about Korro Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Korro Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.